Drug Profile
Edivoxetine
Alternative Names: EDP-125; LY-2216684Latest Information Update: 05 Nov 2023
Price :
$50
*
At a glance
- Originator Eli Lilly and Company
- Developer Eddingpharm; Eli Lilly and Company
- Class Antidepressants; Cyclic ethers; Fluorobenzenes; Morpholines; Small molecules
- Mechanism of Action Adrenergic uptake inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Phase III Attention-deficit hyperactivity disorder
- Discontinued Major depressive disorder
Most Recent Events
- 27 Jun 2023 Eddingpharm plans to submit NDA to the National Medical Products Administration (NMPA) for Attention deficit hyperactivity disorder (ADHD) in China in the second half of 2023 (Eddingpharm pipeline, June 2023)
- 31 Jan 2023 Phase-III clinical trials in Attention-deficit hyperactivity disorder (In children, In adolescents) in China (PO), prior to January 2023 (Eddingpharm pipeline, June 2023)
- 31 Jan 2023 Eddingpharm completes a phase-III trial in Attention-deficit hyperactivity disorder (In children, In adolescents) in China (PO) (Eddingpharm pipeline, June 2023)